Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 55 | 2023 | 92 | 11.460 |
Why?
|
| Graft vs Host Disease | 23 | 2023 | 47 | 4.460 |
Why?
|
| Leukemia, Myeloid, Acute | 16 | 2023 | 45 | 2.990 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 7 | 2023 | 24 | 1.730 |
Why?
|
| Transplantation Conditioning | 23 | 2023 | 35 | 1.470 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2022 | 38 | 0.960 |
Why?
|
| Transplantation, Homologous | 17 | 2023 | 279 | 0.940 |
Why?
|
| Hematologic Neoplasms | 2 | 2020 | 17 | 0.850 |
Why?
|
| Humans | 67 | 2023 | 29851 | 0.800 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 13 | 0.790 |
Why?
|
| Hodgkin Disease | 4 | 2021 | 19 | 0.730 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2023 | 42 | 0.710 |
Why?
|
| Recurrence | 13 | 2023 | 355 | 0.670 |
Why?
|
| Eye Diseases | 4 | 2019 | 7 | 0.660 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 200 | 0.640 |
Why?
|
| Primary Myelofibrosis | 3 | 2023 | 8 | 0.630 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 329 | 0.620 |
Why?
|
| Retrospective Studies | 24 | 2023 | 3325 | 0.620 |
Why?
|
| Cyclophosphamide | 8 | 2023 | 56 | 0.540 |
Why?
|
| Salvage Therapy | 3 | 2021 | 36 | 0.520 |
Why?
|
| Middle Aged | 27 | 2023 | 9963 | 0.520 |
Why?
|
| Adult | 27 | 2023 | 8748 | 0.520 |
Why?
|
| Transplantation, Autologous | 8 | 2022 | 197 | 0.460 |
Why?
|
| Prognosis | 12 | 2023 | 874 | 0.430 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2021 | 77 | 0.420 |
Why?
|
| Disease-Free Survival | 10 | 2022 | 191 | 0.410 |
Why?
|
| Multiple Myeloma | 2 | 2022 | 30 | 0.400 |
Why?
|
| Calcineurin Inhibitors | 5 | 2023 | 10 | 0.390 |
Why?
|
| Adolescent | 12 | 2023 | 2334 | 0.370 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 18 | 0.370 |
Why?
|
| Male | 23 | 2022 | 15871 | 0.350 |
Why?
|
| Aged | 20 | 2023 | 9621 | 0.350 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2020 | 10 | 0.340 |
Why?
|
| Young Adult | 12 | 2021 | 1969 | 0.340 |
Why?
|
| Allografts | 5 | 2021 | 180 | 0.320 |
Why?
|
| Female | 22 | 2023 | 16430 | 0.290 |
Why?
|
| Survival Rate | 8 | 2021 | 376 | 0.290 |
Why?
|
| Hemoglobin SC Disease | 1 | 2006 | 1 | 0.270 |
Why?
|
| Splenic Diseases | 1 | 2006 | 3 | 0.270 |
Why?
|
| Rituximab | 3 | 2023 | 54 | 0.270 |
Why?
|
| Chromosome Aberrations | 3 | 2021 | 13 | 0.260 |
Why?
|
| Melphalan | 5 | 2023 | 16 | 0.240 |
Why?
|
| Immunosuppressive Agents | 3 | 2020 | 135 | 0.240 |
Why?
|
| Mycoses | 1 | 2023 | 22 | 0.230 |
Why?
|
| Scedosporium | 1 | 2023 | 1 | 0.230 |
Why?
|
| Bacterial Infections | 1 | 2023 | 66 | 0.220 |
Why?
|
| Risk Factors | 5 | 2023 | 2467 | 0.220 |
Why?
|
| Quality of Life | 4 | 2022 | 677 | 0.220 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2023 | 3 | 0.220 |
Why?
|
| Myeloablative Agonists | 2 | 2020 | 2 | 0.220 |
Why?
|
| POEMS Syndrome | 1 | 2022 | 1 | 0.210 |
Why?
|
| Remission Induction | 5 | 2022 | 103 | 0.210 |
Why?
|
| Unrelated Donors | 4 | 2023 | 4 | 0.210 |
Why?
|
| Vidarabine | 4 | 2023 | 11 | 0.200 |
Why?
|
| Drug Resistance | 2 | 2019 | 58 | 0.200 |
Why?
|
| Bone Marrow | 4 | 2023 | 78 | 0.200 |
Why?
|
| Autografts | 2 | 2019 | 32 | 0.200 |
Why?
|
| Hypogonadism | 1 | 2021 | 7 | 0.200 |
Why?
|
| Infertility | 1 | 2021 | 7 | 0.200 |
Why?
|
| Busulfan | 4 | 2023 | 4 | 0.200 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 23 | 0.200 |
Why?
|
| Bone Marrow Transplantation | 4 | 2023 | 34 | 0.200 |
Why?
|
| Roseolovirus Infections | 1 | 2021 | 2 | 0.190 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2021 | 4 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 19 | 0.190 |
Why?
|
| Siblings | 4 | 2022 | 18 | 0.190 |
Why?
|
| Heart Failure | 1 | 2023 | 207 | 0.190 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 79 | 0.190 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2020 | 1 | 0.190 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 40 | 0.190 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 9 | 0.190 |
Why?
|
| Return to Work | 1 | 2021 | 52 | 0.180 |
Why?
|
| Calcineurin | 1 | 2020 | 8 | 0.180 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 2 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 5 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2021 | 82 | 0.180 |
Why?
|
| Infliximab | 1 | 2020 | 16 | 0.180 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2019 | 1 | 0.180 |
Why?
|
| Transplantation, Haploidentical | 1 | 2019 | 1 | 0.170 |
Why?
|
| Survival Analysis | 4 | 2021 | 310 | 0.170 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 411 | 0.170 |
Why?
|
| Steroids | 1 | 2019 | 22 | 0.170 |
Why?
|
| Typhlitis | 1 | 2019 | 1 | 0.170 |
Why?
|
| Mucositis | 1 | 2019 | 3 | 0.170 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 5 | 0.170 |
Why?
|
| Neoplasms | 1 | 2022 | 257 | 0.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 223 | 0.170 |
Why?
|
| Lung Diseases | 1 | 2019 | 46 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2019 | 40 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 86 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 89 | 0.160 |
Why?
|
| Acute Disease | 3 | 2023 | 225 | 0.160 |
Why?
|
| Incidence | 4 | 2023 | 759 | 0.160 |
Why?
|
| Pandemics | 1 | 2020 | 237 | 0.160 |
Why?
|
| Lymphoma | 1 | 2017 | 44 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 1 | 2017 | 10 | 0.150 |
Why?
|
| Cachexia | 1 | 2017 | 11 | 0.150 |
Why?
|
| Child, Preschool | 3 | 2023 | 654 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 507 | 0.130 |
Why?
|
| Chronic Disease | 3 | 2023 | 508 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2020 | 3561 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 1859 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4930 | 0.110 |
Why?
|
| Interleukin-2 | 1 | 2012 | 68 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 36 | 0.110 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 61 | 0.100 |
Why?
|
| Melanoma | 1 | 2012 | 52 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2021 | 685 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2022 | 1953 | 0.090 |
Why?
|
| Vincristine | 2 | 2023 | 27 | 0.090 |
Why?
|
| Tacrolimus | 2 | 2021 | 13 | 0.090 |
Why?
|
| Prednisone | 2 | 2023 | 68 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 252 | 0.090 |
Why?
|
| Doxorubicin | 2 | 2023 | 70 | 0.090 |
Why?
|
| Leukocyte Count | 2 | 2020 | 92 | 0.090 |
Why?
|
| Mutation | 2 | 2023 | 399 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 177 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2020 | 161 | 0.080 |
Why?
|
| Cytarabine | 2 | 2020 | 10 | 0.080 |
Why?
|
| Etoposide | 2 | 2020 | 50 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 332 | 0.080 |
Why?
|
| Registries | 2 | 2020 | 191 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2020 | 1824 | 0.080 |
Why?
|
| Comorbidity | 2 | 2020 | 504 | 0.080 |
Why?
|
| Pain | 2 | 2021 | 397 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 346 | 0.070 |
Why?
|
| Child | 2 | 2021 | 1379 | 0.070 |
Why?
|
| Disease Progression | 2 | 2022 | 812 | 0.070 |
Why?
|
| Splenomegaly | 1 | 2006 | 3 | 0.070 |
Why?
|
| Splenectomy | 1 | 2006 | 7 | 0.070 |
Why?
|
| Erythropoiesis | 1 | 2006 | 6 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 2006 | 9 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2006 | 60 | 0.070 |
Why?
|
| Fever | 1 | 2006 | 40 | 0.070 |
Why?
|
| United States | 2 | 2023 | 2346 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 364 | 0.060 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2023 | 18 | 0.060 |
Why?
|
| Toes | 1 | 2023 | 5 | 0.060 |
Why?
|
| Voriconazole | 1 | 2023 | 8 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2023 | 36 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2023 | 73 | 0.050 |
Why?
|
| Whole-Body Irradiation | 1 | 2022 | 18 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2022 | 23 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2022 | 17 | 0.050 |
Why?
|
| Bortezomib | 1 | 2021 | 5 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 9 | 0.050 |
Why?
|
| Survivors | 1 | 2021 | 57 | 0.050 |
Why?
|
| Canada | 1 | 2020 | 56 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2020 | 16 | 0.050 |
Why?
|
| Lymphocyte Transfusion | 1 | 2020 | 3 | 0.040 |
Why?
|
| Carmustine | 1 | 2020 | 5 | 0.040 |
Why?
|
| Cell Count | 1 | 2020 | 97 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 64 | 0.040 |
Why?
|
| Pyrazines | 1 | 2019 | 11 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2019 | 41 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 56 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 53 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 10 | 0.040 |
Why?
|
| Blood Donors | 1 | 2019 | 5 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 55 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2020 | 110 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 75 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2018 | 4 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 85 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 854 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2017 | 14 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 21 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 30 | 0.040 |
Why?
|
| Mass Screening | 1 | 2018 | 180 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 38 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2018 | 190 | 0.040 |
Why?
|
| Methotrexate | 1 | 2017 | 42 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2017 | 48 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2018 | 141 | 0.040 |
Why?
|
| Inflammation | 1 | 2018 | 347 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 101 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 704 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 456 | 0.020 |
Why?
|